AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program
AEON Biopharma announced positive feedback from the FDA following their January 2026 Biosimilar Biological Product Development Type 2a meeting regarding the analytical similarity strategy for ABP-450, their biosimilar candidate to BOTOX®. The FDA recognized the scientific challenges but supported AEON's analytical approach under the 351(k) biosimil…